RxDoctor Payments Data

Bernard Schneider, PA

Physician Assistant · Wilmington, DENPI 1962459925

Payments from drug & device makers

$1,658in general payments, 2019–2025

Across 92 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$234
  • Novo Nordisk$191
  • AstraZeneca$165
  • Abbott$139
  • Johnson & Johnson$134
  • GSK$104
  • plus $690 from 16 others

What the payments were for

  • Food & beverage$1,658100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,658 in reported general payments places this provider in the 80th percentile of 527 physician assistant providers in Delaware.

See all physician assistant providers in Delaware

Medicare billing

Part B allowed, 2024
$119,082
Medicare patients
410
Services billed
1,618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide94$87,355
EliquisApixaban62$66,465
JardianceEmpagliflozin46$37,188
XareltoRivaroxaban41$31,359
JanuviaSitagliptin Phosphate16$21,894
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr33$21,091
TrulicityDulaglutide20$19,749
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$17,832
JanumetSitagliptin Phos/Metformin Hcl14$14,152
FarxigaDapagliflozin Propanediol13$11,458
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog29$11,386
Breo ElliptaFluticasone/Vilanterol21$10,320
Incruse ElliptaUmeclidinium Bromide15$6,607
Bevespi AerosphereGlycopyrrolate/Formoterol Fum12$4,867
Atorvastatin Calcium234$3,668

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$191$87,35594 claims
PfizerEliquis$75$66,46562 claims
GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta, Incruse Ellipta$104$55,85091 claims
Boehringer IngelheimJardiance$17$37,18846 claims
MerckJanuvia, Janumet$33$36,04730 claims
Johnson & JohnsonXarelto$134$31,35941 claims
Lilly USA, LLCTrulicity$234$19,74920 claims
AstraZenecaFarxiga, Bevespi Aerosphere$165$16,32525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 527 physician assistant providers in Delaware.

Other physician assistant in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →